Prosonix, a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines enabled by its unique particle engineering technology, has appointed Cécile Miles as Chief Business Officer.
In this newly created role, Miles will drive Prosonix’ business development and commercial strategy.
Miles joins Oxford, UK-based Prosonix from the Watson Group (now known as Actavis), the world's third-largest generics company, where she was Commercial Director EU.
Before this role, she was Executive Director of Commercial Development at Ark Therapeutics; Executive Director of Global Business Development at Pliva; and Head of the European Division at Ranbaxy Laboratories. She also spent several years in a variety of commercial roles at Fisons.
Commenting on the appointment, David Hipkiss, Prosonix’ CEO, said: ‘Cécile will play a key role in driving Prosonix’ business development strategy over the coming years as we explore opportunities to capture the full potential value of our portfolio of directly substitutable inhaled generics and novel combination respiratory candidates.’
